Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 39
01
Overview
Phase 3, randomised, double-blind trial in viral pneumonia comparing Tozorakimab with Placebo (2 arms). Primary endpoint: Proportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO) at Day 28. Started Dec 2022; status: recruiting.
02
Drugs
tozorakimab
03
Conditions
viral pneumonia
Beyond the preview
Go deeper on NCT05624450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624450.